Carmustine shortage has led to an increase use of alternative conditioning regimens prior to
autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine …

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for patients with relapsed aggressive non-HodgkinLs lymphoma (NHL). 1, 2 …

We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of
BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen …

The combination of carmustine, etoposide, aracytin, and melphalan (BEAM) conditioning
regimen in autologous stem-cell transplantation (ASCT) is widely used in patients with …

With the advent of new cellular and targeted therapies, treatment options for relapsed and
refractory (r/R) lymphomas have multiplied, and the optimal approach offering the best …

We designed a phase 1-2 study to evaluate the safety and the efficacy of increasing doses of
bendamustine (160 mg/m2, 180 mg/m2, and 200 mg/m2 given on days− 7 and− 6) coupled …

BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem
cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated …

Background Autologous stem cell transplantation (ASCT) following BEAM (BCNU,
etoposide, cytarabine, melphalan) conditioning is standard of care in relapsed low‐and high …

Results Median time to neutrophil> 0.5× 109/l recovery was 10 days in both groups (p=
0.29), while median time to platelet> 50× 109/l recovery was 13 and 14 days after BEAM and …

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or …